Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could earlier aspirin after stroke save more brains?

NCT ID NCT07563673

Disease control Sponsor: Beijing Chao Yang Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving a low-dose aspirin just 2 hours after clot-busting treatment for stroke is better than waiting the standard 24 hours. About 210 adults aged 18-65 who had a stroke will be randomly assigned to get aspirin early or at the usual time. The goal is to see if early aspirin leads to better recovery and fewer complications like re-clogged arteries.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Aspirin (low-dose, 100 mg)
What this could lead to
If successful, this could change guidelines to start aspirin earlier after clot-busting treatment, potentially reducing the risk of re-clogged arteries and improving recovery for stroke patients.
What could go wrong
This is a small, early-phase trial with only 210 participants, so results may not apply to all stroke patients. Giving aspirin earlier also raises a small risk of bleeding in the brain, which the study is carefully monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 210 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age range: 18-65 years old 2. Receive rt PA thrombolytic therapy within 3 hours (including 3 hours) of onset 3. Signs of brain dysfunction lasting for more than 1 hour 4. CT imaging excludes cerebral hemorrhage, and there are no imaging changes corresponding to the patient's physical signs Exclusion Criteria: 1. Age\>65 years old 2. Onset time\>3 hours 3. Accompanied by consciousness disorders, or NIHSS ≥ 20 points 4. CT shows' high-density shadow of middle cerebral artery ' 5. Accompanied by atrial fibrillation or clearly identified as cardioembolic embolism 6. Severe swallowing difficulties, unable to take medication orally 7. Oral anticoagulant medication is currently being taken 8. Accompanied by severe infection or evidence of severe infection 9. Refusal to sign the informed consent form for this study 10. Exclusion criteria for other traditional intravenous thrombolysis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cerebral infarction ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cerebral infarction Thrombolysis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijng Chao-Yang Hospital, Capital Medical University

    Beijing, Beijing Municipality, 100020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.